share_log

Allarity Therapeutics | SCHEDULE 13G: Others

Allarity Therapeutics | SCHEDULE 13G: Others

Allarity Therapeutics | SCHEDULE 13G:其他
美股SEC公告 ·  2024/08/29 17:01

Moomoo AI 已提取核心訊息

Olmsted Investments LLC has filed a Schedule 13G with the Securities and Exchange Commission on August 19, 2024, indicating a significant ownership stake in Allarity Therapeutics, Inc. The Utah-based investment firm reported beneficial ownership of 10,000 shares of Allarity's Series A Convertible Redeemable Preferred Stock, representing 28.6% of the class. The filing, which is a requirement for parties owning more than 5% of a company's stock, specifies that Olmsted Investments LLC has sole voting and dispositive power over the shares. The address of Allarity Therapeutics' principal executive offices is listed as 24 School St., 2nd Floor, Boston, Massachusetts, 02108. Olmsted Investments LLC has certified that the acquisition of these shares is not for the purpose of changing or influencing the control of Allarity Therapeutics, nor is it connected with any transaction that has such purpose or effect.
Olmsted Investments LLC has filed a Schedule 13G with the Securities and Exchange Commission on August 19, 2024, indicating a significant ownership stake in Allarity Therapeutics, Inc. The Utah-based investment firm reported beneficial ownership of 10,000 shares of Allarity's Series A Convertible Redeemable Preferred Stock, representing 28.6% of the class. The filing, which is a requirement for parties owning more than 5% of a company's stock, specifies that Olmsted Investments LLC has sole voting and dispositive power over the shares. The address of Allarity Therapeutics' principal executive offices is listed as 24 School St., 2nd Floor, Boston, Massachusetts, 02108. Olmsted Investments LLC has certified that the acquisition of these shares is not for the purpose of changing or influencing the control of Allarity Therapeutics, nor is it connected with any transaction that has such purpose or effect.
Olmsted Investments LLC在2024年8月19日向美國證券交易委員會提交了13G表格,表示在Allarity Therapeutics, Inc.擁有重要的股權。這家總部位於猶他州的投資公司報告擁有Allarity的A類可轉換可贖回優先股1萬股,佔該類股票的28.6%。該提交表格是對持有公司股票超過5%的各方的要求,規定Olmsted Investments LLC對這些股份擁有獨立的投票權和處置權。Allarity Therapeutics的總部地址爲馬薩諸塞州波士頓市學校街24號2樓,郵編02108。Olmsted Investments LLC已經證明其收購這些股份不是爲了改變或影響Allarity Therapeutics的控制,也與具有此目的或效果的任何交易無關。
Olmsted Investments LLC在2024年8月19日向美國證券交易委員會提交了13G表格,表示在Allarity Therapeutics, Inc.擁有重要的股權。這家總部位於猶他州的投資公司報告擁有Allarity的A類可轉換可贖回優先股1萬股,佔該類股票的28.6%。該提交表格是對持有公司股票超過5%的各方的要求,規定Olmsted Investments LLC對這些股份擁有獨立的投票權和處置權。Allarity Therapeutics的總部地址爲馬薩諸塞州波士頓市學校街24號2樓,郵編02108。Olmsted Investments LLC已經證明其收購這些股份不是爲了改變或影響Allarity Therapeutics的控制,也與具有此目的或效果的任何交易無關。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息